Shanghai Henlius Biotech, Inc.
2696
株式のランク
#4240
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise,... Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
株価
$6.79
時価総額
$3.70B
変化（1日）
-0.74%
変化（1年）
-25.97%
国
CN
取引 Shanghai Henlius Biotech, Inc. (2696)
カテゴリー
Healthcare
Shanghai Henlius Biotech, Inc.（2696）の収益
Jun 2026 時点の収益 TTM: $1.08B
Shanghai Henlius Biotech, Inc. の最新の財務報告によると、現在の収益 (TTM) は $1.08B です。2023 年には $762.14M の収益があり、これは 2022 年の $466.04M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Shanghai Henlius Biotech, Inc. の収益履歴（2017 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.08B | 37.39% |
| 2024 | $784.27M | 2.90% |
| 2023 | $762.14M | 63.53% |
| 2022 | $466.04M | 76.06% |
| 2021 | $264.71M | 194.30% |
| 2020 | $89.95M | 588.80% |
| 2019 | $13.06M | 1,110.39% |
| 2018 | $1.08M | -79.30% |
| 2017 | $5.21M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,071.65% |
US
|
|
| $2.23B | 106.78% |
US
|
|
| $15.74B | 1,361.22% |
AU
|
|
| $6.02B | 458.83% |
NL
|
|
| - | - |
CH
|
